Etrasimod

CAS No. 1206123-37-6

Etrasimod( APD334 | APD-334 | APD 334 )

Catalog No. M10751 CAS No. 1206123-37-6

Etrasimod (APD334) is a potent, selective, centrally available S1P1 receptor antagonist with β-arrestin EC50 of 6.1 nM, internalizes human S1P1 in CHO cells expressing HA tagged S1P1 with IC50 of 1.88 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 61 Get Quote
5MG 104 Get Quote
10MG 172 Get Quote
25MG 332 Get Quote
50MG 500 Get Quote
100MG 628 Get Quote
200MG 895 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Etrasimod
  • Note
    Research use only, not for human use.
  • Brief Description
    Etrasimod (APD334) is a potent, selective, centrally available S1P1 receptor antagonist with β-arrestin EC50 of 6.1 nM, internalizes human S1P1 in CHO cells expressing HA tagged S1P1 with IC50 of 1.88 nM.
  • Description
    Etrasimod (APD334) is a potent, selective, centrally available S1P1 receptor antagonist with β-arrestin EC50 of 6.1 nM, internalizes human S1P1 in CHO cells expressing HA tagged S1P1 with IC50 of 1.88 nM; produces robust lymphocyte lowering effect (IC50=0.1 uM in mice), shows effectivity in mouse experimental autoimmune encephalomyelitis (EAE) model of MS and a rat collagen induced arthritis (CIA) model, orally active.Irritable Bowel Syndrome Phase 2 Clinical(In Vitro):APD334 is a structurally novel, selective, functional antagonist of S1P1. In CHO cells expressing HA tagged S1P1, APD334 is found to have an IC50 value of 1.88 nM. Moderate agonism at human S1P4 and S1P5 is observed but is reduced relative to S1P1, both in terms of potency and efficacy. APD334 is devoid of any agonism or antagonism at human S1P2 and S1P3. APD334 achieves good central exposure following oral dosing and possesses a favorable pharmacokinetic profile in multiple preclinical species. S1P1 activity is maintained in mice (EC50=0.44 nM), rats (EC50=0.32 nM), dogs (EC50=0.34 nM) and monkeys (EC50=0.32 nM).(In Vivo):APD334 has a relatively low systemic clearance (<4% of hepatic blood flow) and high Cmax across all species. In both dog and monkey a significant decrease in volume of distribution (Vss) is observed relative to rodent. Oral bioavailability is in the range of 40–100%, and the terminal phase half-life varied from 6 h in monkey, to as long as 29 h in dog. Rat and monkey t1/2 values for siponimod (another S1P1 modulator currently in human trials) have been disclosed and are 6 and 19 h, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    APD334 | APD-334 | APD 334
  • Pathway
    GPCR/G Protein
  • Target
    Lysophospholipid Receptor
  • Recptor
    Lysophospholipid Receptor
  • Research Area
    Other Indications
  • Indication
    Irritable Bowel Syndrome

Chemical Information

  • CAS Number
    1206123-37-6
  • Formula Weight
    457.4847
  • Molecular Formula
    C26H26F3NO3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 28 mg/mL
  • SMILES
    C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F
  • Chemical Name
    Cyclopent[b]indole-3-acetic acid, 7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydro-, (3R)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Buzard DJ, et al. ACS Med Chem Lett. 2014 Nov 4;5(12):1313-7. 2. Peyrin-Biroulet L, et al. Autoimmun Rev. 2017 May;16(5):495-503. 3. Nielsen OH, et al. Expert Opin Investig Drugs. 2016 Jun;25(6):709-18.
molnova catalog
related products
  • BMS-986020

    BMS-986020 (BMS986020, AM-152) is a potent, selective, orally available LPA1 receptor antagonist for treating idiopathic pulmonary fibrosis.

  • Mocravimod

    A synthetic immunosuppressant that functions as a S1P1 receptor agonist.

  • Amiselimod hydrochlo...

    A novel prodrug S1P receptor modulator lacking S1P3 receptor agonism to avoid bradycardia associated with fingolimod and other S1P receptor modulators.